Back to Search
Start Over
[Interchangeability and substitution of biosimilars].
- Source :
-
Annales pharmaceutiques francaises [Ann Pharm Fr] 2020 Jul; Vol. 78 (4), pp. 277-284. Date of Electronic Publication: 2020 May 07. - Publication Year :
- 2020
-
Abstract
- The rationality of the interchangeability of biosimilars is based on broad scientific evidence and numerous clinical experiences in real life which show no sign of reduced efficacy or different tolerance compared to the original molecule. The substitution of biosimilars (pharmaceutical act) remains widely contested in many countries, notably in France. However, it would make it possible to make very significant savings in a context of major acceleration in health spending. This reluctance is unfounded in light of the quality of biosimilars authorized in Europe and their rigorous evaluation. It is therefore essential to improve the information of health professionals and patients on these biosimilars.<br /> (Copyright © 2020 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.)
Details
- Language :
- French
- ISSN :
- 0003-4509
- Volume :
- 78
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Annales pharmaceutiques francaises
- Publication Type :
- Academic Journal
- Accession number :
- 32387176
- Full Text :
- https://doi.org/10.1016/j.pharma.2020.04.004